Eli Lilly beat earnings. Again. The stock went up. Again. Some analyst raised their price target. Again. This is what passes for financial insight in 2026.
The GLP-1 business is strong. You know what else suggests a stock has room to run? The fact that it's been running. Turns out when a company sells drugs that make people less fat and less diabetic, the revenue goes up. Groundbreaking stuff. Someone get these analysts a Fields Medal.
Here's how price target analysis works: Wait for the stock to go up fifteen percent. Raise your target by twelve percent. Publish a note explaining why you saw this coming all along. Collect your bonus. Die alone.
The beat-and-raise quarter is Wall Street's favorite magic trick. The company beats estimates they helped set three months ago. Then they raise guidance they'll beat again next quarter. Then analysts raise price targets to levels the stock already traded at last week. It's a circle jerk with Bloomberg terminals.
Retail traders will read "more room to run" and think it means something. It doesn't. Every stock has room to run until it has room to fall. That's how prices work. They move. The direction is the surprise part.
GLP-1 drugs are printing money. Lilly's market cap is north of $700 billion. The analyst who raised this price target probably set it at $650 four months ago when the stock was at $720. Now it's at $850 and suddenly there's "more room to run." Must be nice having a job where being consistently late counts as being right.
The funniest part isn't that analysts chase stocks higher. It's that anyone still pretends the price target meant something before they changed it.
Photo by on Unsplash
Leave a Comment